Earnings Feed
Start Free
Home/Filings/4/0001021771-24-000046
4//SEC Filing

Silva Francisco 4

Accession 0001021771-24-000046

CIK 0001505497other
View on SEC.govCompany Profile

Filed

Feb 14, 7:00 PM ET

Accepted

Feb 15, 4:13 PM ET

Size

19.4 KB

Accession

0001021771-24-000046

Insider Transaction Report

Form 4
Period: 2024-02-13
BioRestorative Therapies, Inc.BRTX
Silva Francisco
VP of Research and Development
Transactions
  • Award

    Stock Option

    2024-02-13+394,737→ 394,737 total
    Exercise: $1.45Exp: 2034-02-13→ Common Stock (394,737 underlying)
Holdings

  • Common Stock

    164,644

  • Common Stock

    (indirect: By IRA)
    12,136

  • Stock Option

    Exercise: $3000.00Exp: 2024-02-18→ Common Stock (3 underlying)
    3

  • Stock Option

    Exercise: $3000.00From: 2014-03-12Exp: 2024-03-11→ Common Stock (1 underlying)
    1

  • Stock Option

    Exercise: $3000.00Exp: 2024-10-23→ Common Stock (9 underlying)
    9

  • Stock Option

    Exercise: $3000.00Exp: 2025-09-04→ Common Stock (6 underlying)
    6

  • Stock Option

    Exercise: $3000.00Exp: 2026-06-10→ Common Stock (15 underlying)
    15

  • Stock Option

    Exercise: $3000.00Exp: 2027-07-12→ Common Stock (20 underlying)
    20

  • Stock Option

    Exercise: $3000.00Exp: 2028-10-29→ Common Stock (25 underlying)
    25

  • Stock Option

    Exercise: $5.08Exp: 2031-03-18→ Common Stock (293,479 underlying)
    293,479

  • Stock Option

    Exercise: $5.08Exp: 2031-11-04→ Common Stock (42,059 underlying)
    42,059

  • Stock Option

    Exercise: $2.91Exp: 2033-02-17→ Common Stock (106,762 underlying)
    106,762
Footnotes (5)
  • [F1]Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024.
  • [F2]The option is currently exercisable.
  • [F3]The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 and 21,029 shares in eight nearly equal quarterly installments beginning November 4, 2022 and continuing every three months thereafter until fully vested.
  • [F4]The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
  • [F5]The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.

Documents

1 file

Issuer

BioRestorative Therapies, Inc.

CIK 0001505497

→
Entity typeother

Related Parties

1
  • filerCIK 0001527241

Filing Metadata

Form type
4
Filed
Feb 14, 7:00 PM ET
Accepted
Feb 15, 4:13 PM ET
Size
19.4 KB
View on SEC.gov